Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific ...
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group ...
Researchers at The University of Texas MD Anderson Cancer Center have found that a mitochondrial enzyme, GFER, creates an ...
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
We first analyzed a retrospective cohort of 42 patients with SCLC treated with single-agent ICB or ICB combination (data set A). We then validated our results in a large prospective clinical trial of ...
Researchers have shown HIF1α as a key regulator that induces the cancer-killing capacity of T cells in hypoxic conditions. A team of researchers from the University of Alabama at Birmingham (AL, USA) ...
Metabolic reprogramming in the tumor microenvironment shapes immune function and therapy resistance, offering insights into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback